6533b854fe1ef96bd12ae1dc

RESEARCH PRODUCT

Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population

Silvio BuscemiCarola BuscemiGiovanni MazzolaVito Di MarcoSalvatore PettaFederica SpatolaGrazia PennisiCristiana RandazzoAntonio Craxì

subject

Adultcardiovascular riskmedicine.medical_specialtyPopulationGastroenterologyAsymptomatic03 medical and health sciencesLiver disease0302 clinical medicineatherosclerosiNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineNAFLDmedicineHumansSettore MED/49 - Scienze Tecniche Dietetiche Applicateeducationeducation.field_of_studySettore MED/12 - GastroenterologiaHepatologybusiness.industryFatty liverConfoundingGastroenterologyOdds ratiomedicine.diseasecarotidCardiovascular DiseasesHeart Disease Risk Factors030220 oncology & carcinogenesisABCD studyfatty liver disease030211 gastroenterology & hepatologySteatosismedicine.symptombusiness

description

BACKGROUND AND AIMS Non-alcoholic fatty liver (NAFLD) is a major cause of liver disease worldwide leading also to a higher risk of cardiovascular events. We aimed to evaluate the impact of fatty liver and fibrosis on cardiovascular risk in a general population. METHODS Five hundred and forty-two subjects included in the community-based ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study were recruited. Steatosis (controlled attenuation parameter > 288 dB/m) and severe fibrosis (low risk, liver stiffness measurement [LSM] < 7.9 KPa with M probe and < 5.7 KPa with XL probe; intermediate risk, LSM 7.9-9.5 KPa with M probe and 5.7-9.2 KPa with XL probe; high risk, LSM ≥ 9.6 KPa with M probe and ≥ 9.3 KPa with XL probe) were assessed with FibroScan. Cardiovascular risk was evaluated by the atherosclerotic cardiovascular disease (ASCVD) risk estimator and defined low if < 5%, borderline if 5-7.4%, intermediate if 7.5-19.9% and high if ≥ 20%. Intima-media thickness (IMT) was measured with ultrasound. RESULTS Prevalence of steatosis and of severe fibrosis in this cohort was 31.7% and 4.8%, respectively. ASCVD score was evaluated in patients with and without steatosis and according to the risk of severe fibrosis. By ordinal regression analysis, both steatosis (odds ratio [OR] 1.62, 95% confidence interval [CI] 1.13-2.33, P = 0.009) and severity of fibrosis (OR 1.67, 95% CI 1.18-2.36, P = 0.003) were independent risk factors for a higher ASCVD risk after adjusting for obesity. Subjects with NAFLD, when compared with those without, did not differ for IMT (0.75 vs 0.72 mm; P = 0.11) and IMT ≥ 1 mm (15.6% vs 12.1%; P = 0.24). Higher prevalence of IMT ≥ 1 mm was found in patients at high or intermediate risk of severe fibrosis (24% and 28.6%, respectively) compared with those at low risk (12.1%) (P = 0.03); this association was maintained after adjusting for confounders (OR 2.70, 95% CI 1.01-2.86, P = 0.04). CONCLUSION In the setting of a general adult population, the presence of NAFLD and severe fibrosis are associated with to a higher cardiovascular risk profile, pointing towards the need for specific preventive measures.

10.1111/jgh.15523http://hdl.handle.net/10447/508895